α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析

doi:10.3969/j.issn.1672-5069.2020.03.011

摘要/Abstract

摘要： 目的探讨应用α-干扰素联合利巴韦林治疗儿童慢性丙型肝炎(CHC)患者的疗效和副反应。方法 2016年4月~2018年4月在我院肝病科就诊的42例CHC患儿被随机分为对照组21例和观察组21例,分别接受重组干扰素α-1b或聚乙二醇干扰素α-2a联合利巴韦林治疗48周。观察病毒学和生化学应答率及不良反应情况。结果观察组快速病毒学应答、早期病毒学应答、治疗结束病毒学应答和持续病毒学应答率分别为38.1%、81.0%、90.5%和85.7%,显著高于对照组的16.7%、52.4%、69.1%和64.3%(P<0.05);在治疗4周、12周和48周时,聚乙二醇干扰素α-2a治疗组ALT复常率分别为59.5%、73.8%和83.3%,与对照组相比无统计学差异(分别为47.6%、69.0%和81.0%,P>0.05);聚乙二醇干扰素α-2a治疗组患儿流感样症状和外周血中性粒细胞数减少发生率显著高于国产干扰素治疗组(P<0.05)。结论聚乙二醇干扰素α-2a联合利巴韦林治疗儿童CHC近期疗效较好,但副反应较大,需要根据情况,及时处理,以保证治疗的顺利进行。

关键词: 慢性丙型肝炎, 聚乙二醇干扰素α-2a, 重组干扰素α-1b, 利巴韦林, 病毒学应答, 治疗 , ,

Abstract: Objective To explore the virological and biochemical response in children with chronic hepatitis C (CHC) by using peginterferon-α2a and ribavirin combination treatment. Methods 42 children with CHC were recruited in our hospital between April 2016 and April 2018, and were randomly divided into control (n=21) and observation group (n=21). The patients in control group were treated with recombinant interferon α-1b and ribavirin, while the children with CHC in observation group received peginterferon α-2a and ribavirin combination treatment, and the regimen lasted for 48 weeks. Results The rapid virological response, early virological response, virological response at the end of treatment and sustained virological response in peginterferon α-2a-treated children were 38.1%, 81.0%, 90.5% and 85.7%, significantly higher than 16.7%, 52.4%, 69.1% and 64.3%, respectively, in the control (P<0.05); serum ALT normalization rates at week 4, week 12 and week 48 in the observation group were 59.5%, 73.8% and 83.3%, not significantly different as compared to 47.6%, 69.0% and 81.0%, respectively, in the control (P>0.05); the incidence of influenza-like symptoms and neutropenia in the observation group were much higher than those in the control (P<0.05). Conclusion The combination of peginterferon α-2a and ribavirin in treatment of children with CHC is efficacious with improved virological response, but having some side effects, which should be dealt with in time to complete the regimen.

Key words: Hepatitis C, Pegylated interferon-2a, Recombinant interferonα-1b, Ribavirin, Virological response, Therapy

符垂师,张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3): 344-347.

Fu Chuishi,Zhang Jiewei. Virological and biochemical response in children with chronic hepatitis C by using peginterferon-α2a and ribavirin combination treatment[J]. Journal of Practical Hepatology, 2020, 23(3): 344-347.

参考文献

[1] Vivancos MJ, Moreno A, Quereda C. Treatment of hepatitisc virus with direct-acting antivirals: practical aspects and current situation. Rev Clin Esp, 2018, 218(1):29-37.
[2] Chiu HY, Hui RC, Huang YH, et al. Safety prole of secukinumab in treatment of patients with psoriasis and concurrent hepatitis b or c: a multicentric prospective cohort Study. Acta Derm Venereol, 2018, 98(9): 829-834.
[3] Marciano S, Haddad L, Borzi SM, et al. Access to direct-acting antivirals for the treatment of hepatitis c in a country with limited resources. Rev Gastroenterol Mex, 2018, 83(2): 208-211.
[4] Fan Z, Zhang Q, Chen H, et al. Circulating micrornas as a biomarker to predict therapy efficacy in hepatitis c patients with different genotypes. Microb Pathog, 2017, 112(1): 320-326.
[5] Todorovska B, Caloska-Ivanova V, Dimitrova-Genadieva M, et al. Atorvastatin in combination with pegylated interferon and ribavirin provided high rate of sustained virological response in patients with genotype 3 hepatitis c virus. Open Access Maced J Med Sci, 2019, 7(10): 1641-1648.
[6] Fernández-Caso B, Fernández-Caballero J, Chueca N, et al. Infection with multiple hepatitis c virus genotypes detected using commercial tests should be confirmed using next generation sequencing. Sci Rep, 2019, 9(1): 9264-9264.
[7] Izquierdo L, Mellon G, Buchaillet C, et al. Prevalence of hepatitis e virus and reassessment of HIV and other hepatitis virus seroprevalences among french prison inmates. PLoS One, 2019, 14(6): e0218482-e0218482.
[8] Zubkin ML, Shchepetkova GS, Balkarova OV, et al. Successful hepatitis C virus eradication in a hemodialysis patient with 2k/1b chimera genotype: a case report and literature review. Gastroenterology Res, 2019, 12(3): 176-180.
[9] 段军民, 李素森, 刘丽珍, 等. 聚乙二醇干扰素α-2a与普通干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者疗效比较和影响疗效的预测因素分析. 实用肝脏病杂志, 2018, 21(1): 64-67.
[10] Igarashi A, Furusyo N, Ogawa E, et al. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis c: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open, 2019, 9(6): e023405.
[11] Mohamed AA, Abd Almonaem ER, Mansour AI, et al. Importance of studying the levels of hepcidin and vitamin d in egyptian children with chronic hepatitis c. J Transl Int Med, 2019, 7(1): 15-21.
[12] Lee JY, Cortese M, Haselmann U, et al. Spatiotemporal coupling of the hepatitis c virus replication cycle by creating a lipid droplet- proximal membranous replication compartment. Cell Rep, 2019, 27(12): 3602-3617.
[13] Xue W, Liu K, Qiu K, et al. A systematic review with meta-analysis: is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with hcv recurrence after liver transplantation? Int J Infect Dis, 2019, 83(1):56-63.
[14] Lagging M, Wejstl R, Duberg AS, et al. Treatment of hepatitis c virus infection for adults and children: updated swedish consensus guidelines 2017. Infect Dis (Lond), 2018, 50(8): 569-583.
[15] Preda CM, Baicus C, Sandra I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis c virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy. United European Gastroenterol J, 2019, 7(5): 699-708.
[16] Ide K, Sato I, Imai T, et al. Comparison of the safety profiles of pegylated interferon α-2a and α-2b administered in combination with ribavirin for chronic hepatitis c infection: a real-world retrospective cohort study. Biol Pharm Bull, 2016 , 39(12): 2060-2065.
[17] Sood A, Midha V, Halli SS, et al. Impact of "sambhav" program (financial assistance and counselor services) on hepatitis c pegylated interferon alpha treatment initiation in india. Int J Health Policy Manag, 2018, 7(12): 1138-1144.
[18] Abdel-Moneim A, Abood A, Abdel-Gabaar M, et al. Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis c virus genotype 4 patients. Clin Exp Hepatol, 2018, 4(3): 191-196.
[19] Yang J, Yang G1, He H, et al. Association of characteristics of hbv quasispecies with hepatitis b surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients. Antivir Ther, 2018, 23(7): 567-574.
[20] Kabashima T, Tonooka K, Takada M, et al. Simultaneous assay for protease activities of hepatitis c virus and human immunodeficiency virus based on fluorescence detection. Sci Rep, 2019, 9(1): 9150-9150.
[21] Nii-Trebi NI, Brown CA, Osei YD, et al. Core encoding sequences of hepatitis c virus in ghanaian blood donors are predominantly mosaics of different genotype 2 strains and cannot distinguish subtypes. BMC Infect Dis, 2019, 19(1): 533-533.
[22] Fujita K, Mimura S, Iwama H, et al. Serum mirnas predicting sustained hbs antigen reduction 48 weeks after pegylated interferon therapy in hbe antigen-negative patients. Int J Mol Sci, 2018, 19(7): E1940.
[23] Jun DW, Ahn SB, Kim TY, et al. Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in hepatitis b e antigen-positive hepatitis b patients: a randomized, multicenter, phase iiib open-label study (potent study). Chin Med J (Engl), 2018, 131(14): 1645-1651.
[24] Palesch D, Bosinger SE, Mavigner M, et al. Short-Term pegylated interferon α2a treatment does not significantly reduce the viral reservoir of simian immunodeficiency virus-infected, antiretroviral therapy-treated rhesus macaques. J Virol, 2018, 92(14): e00279.
[25] 史罗明, 周根法, 孙冬林. 聚乙二醇干扰素-α-2a治疗血清低水平HBsAg阳性的慢性乙型肝炎患者临床结局预测研究. 实用肝脏病杂志, 2018, 21(4): 565-568.
[26] 周思思, 沈有秀, 李娟, 等. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化. 实用肝脏病杂志, 2018, 21(5): 689-692.
[27] 曹风华, 经继生, 赵伟, 等. 大剂量普通α-干扰素与聚乙二醇化α-干扰素联合利巴韦林治疗慢性丙型肝炎患者临床疗效及安全性比较研究. 实用肝脏病杂志, 2018, 21(5): 729-732.